Antibodies
Dexamethasone (DHAP)
- 貨號 Cat. No.
- S1322
- 規格 Size
- 10mM/1mLã€50mg
- 品牌 Brand
- Selleckchem
Description
Dexamethasone (DHAP)
Dexamethasone (DHAP) is an anti-inflammatory and immunosuppressant.
| Size | Price | Stock | Quantity | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| |||||||||||
Distributor Tel: +886-2-2827-1197jimmy@new.abscience.com.tw
Biological Activity
Dexamethasone is a potent synthetic member of the glucocorticoid class of steroid drugs. It acts as an anti-inflammatory and immunosuppressant. Its potency is about 20-30 times that of the naturally occurring hormone hydrocortisone and 4-5 times of prednisone.[1]
Chemical Information
Download Dexamethasone (DHAP) SDF
| Molecular Weight (MW) | 392.46 |
|---|---|
| Formula | C22H29FO5 |
| CAS No. | 50-02-2 |
| Storage | 3 years -20℃Powder |
|---|---|
| 6 months-80℃in DMSO | |
| Syonnyms | Decadron |
| Solubility (25°C) * | In vitro | DMSO | 79 mg/mL (201 mM) |
|---|---|---|---|
| Water | <1 mg/mL (<1 mM) | ||
| Ethanol | 6 mg/mL (15 mM) | ||
| In vivo | 30% PEG400/0.5% Tween80/5% propylene glycol, | 30 mg/mL | |
| * <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. | |||
| Chemical Name | (8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,11,12,13,15,16,17-octahydro-6H-cyclopenta[a]phenanthren-3(9H,10H,14H)-one |
|---|
Preparing Stock Solutions
| Stock Solution (1ml DMSO) | 1mM | 10mM | 20mM | 30mM |
|---|---|---|---|---|
| Mass(mg) | 0.39246 | 3.9246 | 7.8492 | 11.7738 |
Customer Reviews (2)
 Click to enlarge | Rating | |
| Source | Oncogene, 2013, 32(10), 1316-29.. Dexamethasone (DHAP) purchased from Selleck | |
| Method | Fluorescence/immunofluorescence microscopy | |
| Cell Lines | MDA-MB-231 cells | |
| Concentrations | 100 nM | |
| Incubation Time | ||
| Results | dexamethasone and largazole, in combination with E-cadherin expression, prevented the cells from overlapping each other(Figure a). Dexamethasone and largazole also modestly increased E-cadherin localization to the cell–cell periphery, and combination of the two drugs caused a more complete E-cadherin junctional localization than either agent alone(Figure b). E-cadherin expression and dexa-methasone and largazole treatment each decreased invasiveness, and combined E-cadherin expression and Dex.+ Larg. Treatment reduced invasion more than either manipulation alone (Figure c). |
Product Citations (1)
